The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses

Journal of Virology

Volumn 85, Issue 23, 2011, Pages 12825-12829

  Pica, Natalie ^a   Iyer, Arun ^a   Ramos, Irene ^a   Bouvier, Nicole M ^a   Fernandez Sesma, Ana ^a   García Sastre, Adolfo ^a   Lowen, Anice C ^a,b   Palese, Peter ^a   Steel, John ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AVIAN INFLUENZA VIRUS; C57BL 6 MOUSE; CONTROLLED STUDY; DBA 2 MOUSE STRAIN; DISEASE MODEL; EXPERIMENTAL INFECTION; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; INFECTION SENSITIVITY; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H3N8; INOCULATION; LD 50; LUNG PARENCHYMA; MOUSE; MOUSE STRAIN; NONHUMAN; NOTE; PRIORITY JOURNAL; STRAIN DIFFERENCE; SWINE INFLUENZA VIRUS; VIRUS RECOMBINANT; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; ORTHOMYXOVIRIDAE INFECTIONS; VIRUS REPLICATION;

CERCOPITHECINE HERPESVIRUS 1; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MUS; ORTHOMYXOVIRIDAE; SWINE INFLUENZA VIRUS;

EID: 81255179897     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05930-11     Document Type: Note

References (27)

1. Alberts, R., et al. 2010. Gene expression changes in the host response between resistant and susceptible inbred mouse strains after influenza A infection. Microbes Infect. 12:309-318.
2. Boon, A. C., et al. 2009. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J. Virol. 83:10417-10426.
3. Boon, A. C., et al. 2010. Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. J. Virol. 84:7662-7667.
4. Bouvier, N. M., and A. C. Lowen. 2010. Animal models for influenza virus pathogenesis and transmission. Viruses 2:1530-1563.
5. DiMenna, L. J., and H. C. Ertl. 2009. Pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333:291-321.
6. Dushoff, J., J. B. Plotkin, C. Viboud, D. J. Earn, and L. Simonsen. 2006. Mortality due to influenza in the United States-an annualized regression approach using multiple-cause mortality data. Am. J. Epidemiol. 163:181-187.
7. Foppa, I. M., and M. M. Hossain. 2008. Revised estimates of influenzaassociated excess mortality, United States, 1995 through 2005. Emerg. Themes Epidemiol. 5:26.
8. Girard, M. P., J. S. Tam, O. M. Assossou, and M. P. Kieny. 2010. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 28:4895-4902.
9. Hai, R., et al. 2010. PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J. Virol. 84:4442-4450.
10. Hale, B. G., et al. 2010. Mutations in the NS1 C-terminal tail do not enhance replication or virulence of the 2009 pandemic H1N1 influenza A virus. J. Gen. Virol. 91:1737-1742.
11. Johnson, N. P., and J. Mueller. 2002. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76:105-115.
12. Kashyap, A. K., et al. 2010. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog. 6:e1000990.
13. Lambert, L. C., and A. S. Fauci. 2010. Influenza vaccines for the future. New Engl. J. Med. 363:2036-2044.
14. Memoli, M. J., et al. 2009. An early 'classical' swine H1N1 influenza virus shows similar pathogenicity to the 1918 pandemic virus in ferrets and mice. Virology 393:338-345.
15. Minor, P. D. 2010. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin. Infect. Dis. 50:560-565.
16. Nabel, G. J., and A. S. Fauci. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16: 1389-1391.
17. Neumann, G., T. Noda, and Y. Kawaoka. 2009. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931-939.
18. Palese, P. 2006. Making better influenza virus vaccines? Emerg. Infect. Dis. 12:61-65.
19. Pizzi, M. 1950. Sampling variation of the fifty percent end-point, determined by the Reed-Muench (Behrens) method. Hum. Biol. 22:151-190.
20. Ramos, I., et al. 2011. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. J. Virol. 85:4421-4431.
21. Smith, G. J., et al. 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459:1122-1125.
22. Solórzano, A., J. Ye, and D. R. Perez. 2010. Alternative live-attenuated influenza vaccines based on modifications in the polymerase genes protect against epidemic and pandemic flu. J. Virol. 84:4587-4596.
23. Srivastava, B., et al. 2009. Host genetic background strongly influences the response to influenza A virus infections. PLoS One 4:e4857.
24. Thakur, A. K., and W. L. Fezio. 1981. A computer program for estimating [50LD] and its confidence limits using modified Behrens-Reed-Muench cumulant method. Drug Chem. Toxicol. 4:297-305.
25. Thompson, W. W., et al. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340.
26. Thompson, W. W., et al. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186.
27. Ye, J., et al. 2010. Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog. 6:e1001145.